Meitheal Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, expanded its biosimilars portfolio with an exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. (HKF) to market and distribute three biosimilars in the U.S. The agreement covers biosimilars for oncology medications pegfilgrastim and filgrastim as well as follitropin alp...